<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334071</url>
  </required_header>
  <id_info>
    <org_study_id>RHM CAN 0960</org_study_id>
    <secondary_id>13/YH/0354</secondary_id>
    <nct_id>NCT03334071</nct_id>
  </id_info>
  <brief_title>Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients</brief_title>
  <acronym>EMBRACE</acronym>
  <official_title>Exercise regiMens Before and duRing Advanced Cancer thErapy: A Pilot Study to Investigate Improvements in Physical Fitness With Exercise Training Programme Before and During Chemotherapy in Advanced Lung Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Southampton NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial Phase: Pilot

      Indication: Stage IIIB/IV NSCLC

      Primary Objective: To assess the feasibility and tolerability of exercise training during
      palliative chemotherapy.

      Secondary Objective: 1) To assess fitness levels in patients undergoing palliative
      chemotherapy, and to explore whether exercise training can prevent a reduction in fitness.

      2) To determine the baseline fitness, as assessed by cardiopulmonary exercise testing (CPET),
      of a cohort of patients with stage IIIb/IV non small cell lung cancer who are about to
      initiate treatment with chemotherapy 3) To compare patients enrolled in the EMBRACE
      randomized controlled trial (RCT) with those who decline.

      4)To investigate any relationship between baseline fitness and outcomes including therapy
      related complications, response, and survival in those patients who decline exercise training
      or are randomized to observation.

      5) To assess the feasibility of the translation of in-hospital exercise training to
      home-based training during chemotherapy.

      6) To document the effects of chemotherapy on cellular energetics and mitochondrial function.

      Rationale: Chemotherapy has a detrimental effect on physical fitness, and this effect can be
      later reversed by training. The investigators wish to understand the mechanism of this
      detrimental effect, and investigate whether it can be prevented or attenuated by giving
      chemotherapy concurrently with exercise training.

      Trial Design: Randomised controlled study (1:1) comparing chemotherapy alone, with
      chemotherapy plus exercise training. A subgroup of patients will have muscle biopsies.
      Patients who decline randomisation will be offered enrolment into an observational arm.

      Sample size : 100 patients (to include 48 who will be randomised, and 52 in the observational
      arm).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EMBRACE is a multi-centre pilot study for 100 patients with EGFR negative NSCLC undergoing
      first line platinum based chemotherapy. It is a prospective randomised (1:1) 2-arm controlled
      study. A nested mechanism study will be performed in a sub group of patients willing to have
      muscle biopsies.

      Patients will be randomised to the exercise intervention or the control arm. All patients
      will undergo standard chemotherapy with gemcitabine and carboplatin (or equivalent) for 12
      weeks. Patients randomised to the intervention arm will undergo concurrent exercise training
      during their 12 weeks of chemotherapy treatment. Patients randomised to the control arm will
      undergo chemotherapy only. During the 12 weeks of the study, assessments will be performed on
      all patients (including CPET tests and HRQL questionnaires). The exercise training sessions
      and study assessments will not affect timing of delivery of chemotherapy. Patients who
      decline randomisation will be offered entry into an observational study.

      The follow-up phase will commence when patients have completed 12 weeks of chemotherapy, or
      sooner for patients who stop chemotherapy early due to progressive disease or toxicity.
      During the follow-up phase data will be for survival and to follow any AEs related to study
      procedures. AEs not related to study procedures will not require follow up. Ongoing
      chemotherapy after week 12 will be as per investigator and patient choice, and may include
      further induction cycles, maintenance chemotherapy, or observation.

      In a subgroup of willing patients muscle biopsies will be performed at baseline, during
      chemotherapy, and after completion of chemotherapy.

      TRIAL OUTCOME MEASURES

      The primary outcome variables for this feasibility and tolerability study will be adherence
      to the exercise training program, and adverse events.

      The secondary outcome variables will be response to chemotherapy, fitness levels as measured
      by Cardiopulmonary Exercise Testing (CPET), Time to get up and go test (TUG), grip strength,
      bioimpedance, CT measures of cancer cachexia, and Montreal score, cancer related symptoms,
      HRQL, and activity levels.

      The exploratory outcome variables will be overall survival, toxicity, and biomarkers of
      stress and cellular energetics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2014</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Exercise intervention</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Cardiopulmonary exercise testing assessor, outcome/toxicity assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants completing exercise sessions as a function of the whole programme.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adherence to the exercise training program</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Common Terminology on Complications (CTC AE v4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fitness levels as measured by Cardiopulmonary exercise testing (CPET)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Physical fitness - oxygen uptake at anaerobic threshold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed up and go test (TUG)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Physical fitness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip strength</measure>
    <time_frame>12 weeks</time_frame>
    <description>Physical fitness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal score - Prognostic survival score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Non small cell lung cancer stage, CRP, albumin, lactic acid dehydrogenase (LDH) and absolute neutrophil count/lymphocyte count ratio (N/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>FACT-L quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>Dukes Activity Status Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>International Physical Activity Questionnaire (IPAQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>Godin Leisure Time Questionnaire (GLTEQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients will wear a Sensewear Pro3 activity monitor (armband) or similar e.g. AX3 3-Axis Logging Accelerometer (wristband) for 72 hours. Number of steps in a 72 hours period will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to chemotherapy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cross sectional imaging will be performed within 12 days of the third cycle of chemotherapy, to assess response to treatment. Scans will be reported according to the Response Evaluation Criteria for Solid Tumours (RECIST Version 1 http://www.irrecist.com/recist/recist-in-practice/01.html).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fitness levels as measured by Cardiopulmonary exercise testing (CPET)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Physical fitness - oxygen uptake at peak exercise</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Non Small Cell Lung Cancer Stage IIIB</condition>
  <condition>Non Small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Exercise Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the intervention arm will participate in a supervised in-hospital, exercise training program on a cycle ergometer before and during chemotherapy. At week 5-6 there will be a transition period of in-hospital to home-based exercise training (at this point we will perform the exercises that they will perform at home in the in-hospital environment to ensure that the patient understands the home-based exercise training programme) and then week 7-12 will be home-based exercise training only with telephone support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the control arm will not undergo an exercise training program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients who do not enrol in RCT will be enrolled in the observational arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>High intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session.
The supervised in-hospital exercise training sessions will last &lt;1 hour, exercise training intensities will be individually tailored to each CPET. Exercise training will involve repeated exercise bouts of 3 minutes at a moderate exercise intensity (80%AT) followed by 2 minutes of exercise at a high intensity (50%Î”) for a predetermined amount of time.
The home-based training programme will involve stair climbing (where possible) and brisk walking to achieve heart rates commensurate with those achieved during the in-hospital exercise training sessions.</description>
    <arm_group_label>Exercise Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, aged over 18 years old

          -  Histologically or cytologically confirmed NSCLC (adenocarcinoma, squamous cell
             carcinoma, large cell carcinoma, undifferentiated carcinoma or other)

          -  Stage IIIb/IV disease

          -  Patients being treated with first line gemcitabine and platinum based chemotherapy
             (other equivalent regimens may be considered on discussion with Judith Cave)

          -  Performance status 0-2 (PS 2 have to be deemed fit enough to complete all cycles of
             chemotherapy).

        Exclusion Criteria:

          -  Unable to consent

          -  Under 18 years

          -  Unable to perform CPET

          -  Significant cardiac ischaemia of &gt; 1.5mm symptomatic and &gt; 2mm asymptomatic observed
             on the baseline ECG

          -  Weight of &gt;145kg (weight limit for cycle ergometer)

          -  Any other contraindication to CPET based on ACCP/ATS Guidelines and summarised in the
             table below.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandy Jack, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Southampton NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith Cave, PhD</last_name>
    <phone>023 8120 5308</phone>
    <email>judith.cave@uhs.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Malcolm A West, PhD</last_name>
    <phone>023 8120 5308</phone>
    <email>m.west@soton.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Legett</last_name>
      <phone>02381205308</phone>
      <email>Samantha.leggett@uhs.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Michael PW Grocott, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith Cave, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronan Astin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Malcolm A West, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Ottensmeier, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

